Category: Health Care

Surgeon explains the coronavirus hoax

Read the Contagion Myth to learn more and dazzle your downline with how smart you are! Chapter 2 is about electricity and disease and chapter 15 is about 5G.

Why is electricity and 5G a part of the virus conversation, you ask? We explain why in this report below:

The Hidden Dangers of Electricity Are a Mortal Threat to Humanity

Raw audio file: https://aim4truth.org/surgeon-says-masks-do-not-work-mp4/

Continue your citizen education:

Face Masks for the Walking Dead

Ohio Citizens Demand Their Civil Rights

New Ohio lawsuit re. COVID hoax

COMPLAINT, Michael Renze et al v. Michael DeWine et al, Case No. 3:20-cv-1948, Judge James G. Carr, filed Sep. 01, 2020  (N.D. Ohio, 2020).

Introduction and Prayer for Relief

Over 110 years ago, at a time when medicine was not yet sufficiently advanced to have developed penicillin and the germ theory of medicine was still new, the Supreme Court of the United States made a ruling related to a citizen’s rights in healthcare that has remained largely unaddressed to this day. Over the century plus of time that has since passed the court has decided many critical cases revolving around individual rights that have never been squared with Jacobson.Jacobson v. Massachusetts, 197 U.S. 11 (1905).

A century ago many of our most sacred and fundamental rights were still being sorted out. Suffrage had not yet occurred, civil rights barely existed, critical cases on fundamental rights such as interstate travel and bodily privacy had not come into play and the administrative state that we live in today simply did not exist.

Today, under the guidance of an unelected administrative structure, many of the rights our Supreme Court has determined are fundamental under our Constitution are being denied. These fundamental rights are being denied, not out of prudence, they are being denied due to unfounded fear and intentional manipulation. So successful is this manipulation that even our esteemed Chief Justice, the Honorable Justice Roberts, was misled in a recent decision.

But all is not lost. In its wisdom, the Jacobsoncourt made clear that it never intended its decision to bar further review. To the contrary, the Court in Jacobsonspecifically stated:“Before closing this opinion, we deem it appropriate, in order to prevent misapprehension as to our views, to observe –perhaps to repeat a thought already sufficiently expressed, namely –that the police power of a State, whether exercised by the legislature or by a local body acting under its authority, may be exerted in such circumstances or by regulations so arbitrary and oppressive in particular cases as to justify the interference of the courts to prevent wrong and oppression.” (Id, 197 US 38)

In recent months, entire states have been imprisoned without due process and with the clear threat to impose such lockdowns again, interstate travel has been severely restricted, privacy rights have been devastated, numerous business takings without compensation, and many regulations being implemented without statutory process requirements under the guise of a health emergency that is roughly as dangerous as a seasonal influenza outbreak. The plaintiffs in this case have all been injured in various capacities by these unconstitutional actions, and without action by the Court, will be left without redress.

More terrifying, without action by the Court, the Court will be setting future precedent that will allow states to withhold fundamental Constitutional rights, in violation of US Supreme Court precedent, circumventing the various levels of scrutiny applied to such rights, and justify such actions under public health emergency orders without subjecting those orders to any real review –just trust the bureaucrats because they are the experts.

We humbly ask the Court in this case to:

  1. Reaffirm its position as a coequal branch of the government.

2. Reaffirm the US Constitution is the supreme law of the land and that rights, especially fundamental rights, may not be abridged unless necessary to serve a compelling governmental interest, and that even then, those restrictions must be narrowly tailored to meet acompelling governmental interest.

3. Ensure there is an opportunity for redress under any emergency declaration

4. Recognize that the political process and operative orders are invalid if based on false or misleading information (cite rule making case in admin law) and recognize the criticality that all future emergency orders be based and maintained on clear, honest facts -particularly when such orders are infringing on Constitutional rights.

Underlying all of this, and the foundation of this case is this question: if an emergency can be declared without the appropriate level of review based on the rights being limited, and under the guise of that emergency all rights are only subject to a rational basis review, how then do any previous judicial opinions or Constitutional principles have any meaning whatsoever?

Further, if under the same circumstances different levels of scrutiny are applied to the various rights being limited under an emergency declaration than would otherwise be applicable, what is the value of having various levels of review?

Read the entire complaint here.

Moderna Insider Trading Reports

Moderna (NASDAQ: MRNA) insider trading reports (Form 4)

CEO Stephan Bancel

Key officers and directors: Sell, Sell, Sell!

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

Owner Filings Transaction Date Type of Owner
Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer
Zaks Tal Zvi 0001690927 2020-07-27 officer: Chief Medical Officer
Hoge Stephen 0001760669 2020-07-23 officer: President
NABEL ELIZABETH G 0001619929 2020-07-15 director
Tallett Elizabeth E 0001192460 2020-07-01 director
HENDERSON LORI M. 0001221127 2020-06-18 officer: General Counsel and Secretary
Meline David W 0001444612 2020-06-08 officer: Chief Financial Officer
Kim Lorence H. 0001643746 2020-06-02 officer: Chief Financial Officer
AFEYAN NOUBAR 0001222012 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV, L.P. 0001503559 2020-05-21 10 percent owner
Flagship Ventures Fund IV General Partner LLC 0001508051 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV-Rx, L.P. 0001590973 2020-05-21 10 percent owner
Andres Juan 0001760670 2020-05-13 officer: See remarks
SAGAN PAUL 0001035440 2020-04-29 director
LANGER ROBERT 0001239757 2020-04-29 director
Nader Francois 0001365343 2020-04-29 director
Horning Sandra 0001638709 2020-04-29 director
Slaoui Moncef 0001712369 2020-04-29 director
Berenson Stephen 0001760671 2020-04-29 director
LEE JENNIFER LING 0001675118 2020-03-09 officer: Chief Accounting Officer

moderna 1

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

stephane bancel

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurcih, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

. . . . . . .

FYI. Ole Stevie boy has been selling his stock out since Nov. 2019.

No buys. All sells.

https://www.fbcoverup.com/docs/library/2020-08-03-Stephane-Bancel-CEO-Moderna-Inc-Form-D-Insider-Trading-Report-SEC-accessed-Aug-03-2020.pdf

bancel stephane

https://yuzuha.substack.com/p/interview-with-moderna-ceo-stephane

. . . . . . .

Moderna’s latest Proxy Statement Form DEF 14A dated Apr. 10, 2020

Massive Wellcome Trust conflict of interest

Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,

Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/

Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019

This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.

That is illegal stock manipulation and should land him and his CEO in jail.

C’mon Bill Barr, do your job.

stephane bancel 2

https://www.sec.gov/Archives/edgar/data/1682852/000119312520103908/d915867ddefa14a.htm

Moderna, Inc. (Filer) CIK0001682852 (see all company filings)

IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

MANAGEMENT

Executives, non-executive directors and director nominee

The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020.

Name Age Position
Executives:
Stéphane Bancel (1) 47 Chief Executive Officer and Director
Juan Andres (1) 55 Chief Technical Operations and Quality Officer
Marcello Damiani 50 Chief Digital and Operational Excellence Officer
Tracey Franklin 40 Chief Human Resources Officer
Lori Henderson, J.D. (1) 58 General Counsel and Corporate Secretary
Stephen Hoge, M.D. (1) 44 President
Lorence Kim, M.D. (1) 45 Chief Financial Officer
Tal Zaks, M.D., Ph.D. (1) 54 Chief Medical Officer
Non-Executive Directors:
Noubar B. Afeyan, Ph.D. (4)(5) 57 Chairman, Director
Stephen Berenson (2)(3) 59 Director
Robert Langer, Sc.D. (4) 71 Director
Elizabeth Nabel, M.D. (4)(5) 68 Director
François Nader, M.D.(5) 63 Director
Israel Ruiz(2)(3) 48 Director
Paul Sagan (2)(3) 61 Director
Moncef Slaoui, Ph.D.(5) 60 Director
Director Nominee:
Sandra Horning, M.D. 71 Director nominee
(1) Executive officer
(2) Member of the Audit Committee
(3) Member of the Compensation and Talent Committee
(4) Member of the Nominating and Corporate Governance Committee
(5) Member of the Product Development Committee

These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus.

https://www.sec.gov/Archives/edgar/data/1682852/000119312518341958/d611137ds1a.htm

moderna edgar search

.

moderna registration

“Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.”

moderna prospectus summary

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022435/xslF345X03/form4.xml

non derivatives securities 1

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022138/xslF345X03/form4.xml

non derivatives securities 2

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 3

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 4

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021763/xslF345X03/form4.xml

non derivatives securities 5

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021495/xslF345X03/form4.xml

non derivatives securities 6

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021332/xslF345X03/form4.xml

non derivative security 7

https://www.sec.gov/Archives/edgar/data/1443340/000089924320018777/xslF345X03/doc4.xml

non derivatives securities 8

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020892/xslF345X03/form4.xml

non derivatives securities 9

https://www.sec.gov/Archives/edgar/data/1443340/000110465920079182/xslF345X03/a4.xml

non derivatives securities 10

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020206/xslF345X03/form4.xml

non derivatives 11

https://www.sec.gov/Archives/edgar/data/1443340/000112760220019726/xslF345X03/form4.xml

non derivatives 12

https://www.sec.gov/Archives/edgar/data/1443340/000112760220018531/xslF345X03/form4.xml

non derivatives 13

The above screen captures are but a few of 120 SELLS from late 2019 to current

See full list of Stephane Bancel Form 4 insider trading reports

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001443340

Here’s a full list of the Moderna Insiders

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

moderna insiders

moderna stock exchange

See actual chart entries with hot links above

moderna chart

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurich, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

bb biotech

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

.

Executives

Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.

Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from

10

Table of Contents

2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.

Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.

Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.

Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.

Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.

Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.

Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

11

Table of Contents

Non-executive directors

Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.

Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.

Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.

Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.

François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail

12

Table of Contents

Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.

Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.

Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.

Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.

Director nominee

Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to

13

Table of Contents

2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.

. . . . . . .

This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018.

It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council)

https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm

.

The Propaganda of Dr. Shiva

Not so fast Dr. Shiva….we see the Hillary Clinton sycophant you are. But first let’s catch this audience up on some details about your past claims to have invented email.

Shiva’s claims about being ‘the inventor of email’ are bogus, propaganda, Pilgrims Society smokescreen to put a patent claims buffer between IBM/Lotus and everyone else (the then chosen platform for the NWO)

shiva patent

Shiva Ayyadurai. (Awarded Dec. 23, 2003). U.S. Pat. No. 6,668,281, Relationship Management System and Method Using Asychronous Electronic Messaging. U.S. Patent Office.

Shiva Ayyadurai 1

In his 1999 patent, https://www.vashiva.com/pdf/vashiva_pat11.pdf, Shiva only cites IBM Notes, and IBM Domino as prior art that was reviewed. Note: This was THE groupware system that the Highlands Group, DoD Office of Net Assessment and their Pilgrims Society handlers were counting on to implement the “IBM Internet of Things.” Notably, hindsight shows us that at this time, IBM had already founded the IBM Eclipse Foundation (Nov. 29, 2001) with Leader Technologies Ne’er-do-well patent attorney, James P. Chandler, III, and IBM Eclipse was already giving away Leader inventions (including its Leader Mail inventions for use with its social backbone), that they had stolen, to everyone in Silicon Valley, government, education, commerce and military.

This disclosure alone shows the Examiner, or Shiva, or both, were brain dead in their examination of “prior art” to meet the “novel and nonobvious” standards for patentability. Curiously, the “patent wrapper” for this patent does not provide the customary the file drawer for this filing, as it should do.

By the late 1990’s, numerous email systems with the exact features of Inbox, Outbox, etc. Groups, sorting, filters, etc. were in wide use. Those systems included: Leader Mail, Microsoft Outlook, Microsoft Exchange, Novel Groupwise, Novel Groupwise Email, Hotmail, YahooMail, Lotus Notes, Lotus cc:Mail, AT&T Mail, AT&T Access (DOS version), AT&T AccessPlus 3.0 (Windows version), CompuServe (csmail), GEIS (mark400), MCI Mail, SPRINT Mail, X-400, BITNET, AOL Mail (“You’ve got mail.”)

.

The patent attorney handling this patent is Khaled Shami (former patent Examiner) https://www.linkedin.com/in/khaled-shami-0a27a17/ who says he is in the firm of BUCHANAN, INGERSOLL & ROONEY PC that does not list him as an attorney. His LinkedIn never mentions BUCHAN either https://www.linkedin.com/in/khaled-shami-0a27a17/

At minimum, this record raises numerous red flags. It is certainly ambiguous. The lack of a “patent wrapper” showing the examiner’s review of the Prior Art begs the question of who is running interference for Shiva? The patent is evidently invalid due to the utter lack of disclosure of significant prior art that the examiner should have used to reject the application as obvious and therefore non-patentable. Certainly Shiva is not justified in saying that he is the “inventor of email.”

This Wikipedia entry is a more accurate reflection of the origins of email.

One serious problem with this Shiva patent is that he does not cite his own prior work, touted on his current website, as prior art. Therefore, his own documents prove this patent bogus.

Here’s Shiva’s history from his site:

V. A. Shiva Ayyadurai. (Apr. 29, 2020). Inventor history, The Inventor o  Email – History. Vashiva.com.

(Note: We have backups of these documents if they disappear from Shiva’s website now that we are bringing attention to them.)

For example, he shows an UNDATED 1981 alleged Westinghouse entry describing his alleged email design in esquisite detail. This document appears to be fake. Notably, Westinghouse is a Pilgrims Society company that is organically tied to NBC, RCA, Marconi and the Pilgrims Society. At minimum, he should have cited this document as prior art on all of his email filings, which would render them all as obvious… if this document really existed, which we now doubt seriously.

He cites an irrelevant 1978 NYU document.

He cites and irrelevant 1978 FORTRAN output that merely mentions email, but there is no association with him.

He shows a newspaper article from Oct. 30, 1980 (p. 8, Sec. 2) of the West Essex Tribune. The article says this project was under “tutelage of Blair Krimmel, head of the math department and the Independent Study program.” Since Shiva does not credit Blair Krimmel as a co-inventor, any subsequent claims are fraudulent (“inequitable conduct”).

His 1981 Westinghouse award discloses:

email shiva

Such prior art disclosure renders his own work as must-cite prior art in subsequent patent applications—thus invalidating his patent claims as not novel and obvious.

His 1981 MIT article is more evidence that his ideas for email were already widely known, and therefore not patentable.

His 1982 Copyright application only serves to show that he disclosed his work to the public in 1982, thus rendering subsequent patent claims impossible to make (since the public already knew about it). Copyrights and patents are very different intellectual property animals.

His 1982 Dr. Leslie Michelson, Ph.D. article is irrelevant to the subject to email.

His subsequent patents 6668281, 6718367, 6718368 (note the last two were issued on the same day, by the same patent examiners). Very odd, unless a fake portfolio is being created as a buffer against patent enemies of the patent office and Shiva’s handlers.

Conclusion: Shiva’s claim to be “the inventor of email” suffers a definite sulfurous odor.

https://www.inventorofemail.com/

https://vashiva.com/innovation/email/vashiva-inventor-history.asp

http://generalinteractive.com/

One of Shiva’s current companies – General Interactive

shiva companies

.

Whoa….all this on Dr. Shiva just on the first trip down the mines! The miners report seeing all kinds of nuggets regarding Dr. Shiva and his connection to Hillary Clinton, the vaccine world, Microsoft, and Bill Gates lying all over the place.

Coal miners 2

While you are waiting for our mining reports, get a glimpse of what we saw down there.

RFK Jr. Asks if Dr. Shiva Owning a Vaccine Company & Partnering with Microsoft is Why He’s Splintering the Movement

Don’t think for one minute that Robert F. Kennedy Jr. is a good guy in this. These are two globalist puppets creating kabuki theater for the vaccine wars. We are going to put both of these vaccine proponents into the bright light of truth.

 

 

 

Vaccine Wars are British Imperial Wars

conquered common cold

.

Raw audio file: https://aim4truth.org/wp-content/uploads/2020/04/Vaccine-Wars.mp3

charles lieber 1

Exposing Harvard’s Chinese Agent Charles Lieber’s “Virus Transmitters”

Recommended links

EXCLUSIVE: Coronavirus Bioweapon– How China Stole Coronavirus From Canada And Weaponized It (watch here Visualizing The Secret History Of Coronavirus)

Watch the exclusive interview of Bioweapons Expert Dr. Francis Boyle on Coronavirus Biological Warfareblocked by the Deep State

https://greatgameindia.com/coronavirus-bioweapon/

https://greatgameindia.com/dr-francis-boyle-creator-of-bioweapons-act-says-coronavirus-is-biological-warfare-weapon/

REVEALED: U.S. government gave $3.7 million grant to Wuhan lab at center of coronavirus leak scrutiny that was performing experiments on bats from the caves where the disease is believed to have originated

Shocking! US gave $3.7 million to China’s Wuhan lab that conducted coronavirus tests on bats

Dr Rashid Buttar BLASTS Gates, Fauci, EXPOSES Fake Pandemic Numbers As Economy Collapses

 

RN Discovers Vaccines are Injecting Cancer

Not just cancer cells…but aborted fetal cells. Read the article link below the video to learn more.

Italy Blows the Lid Off Vaccine Scam. Will No Longer Poison Citizens with Globalist Eugenics.

Italian leaders actually care about the health and well-being of their citizens, Congratulations, Giulia Grillo, for standing up against the globalist agenda of maiming and destroying human life.

ANTI-VACCINE ITALIAN GOVERNMENT SACKS ENTIRE HEALTH EXPERT BOARD

More insight from Jim Stone:

“Italy sacked it’s vaccine scammers, and put in their place 100 percent new people who are not part of the global conspiracy to destroy people with vaccines, and then subsequently and practically immediately discovered that the vaccines have absolutely nothing they are advertised for, which begs the question: What the hell is really in those shots?

Vaccine advocacy group Corvelva, which is not compromised, spearheaded Italy’s investigation into the vaccine scam.

The Eugenicists are up in arms over Corvelva, a vaccine advocacy group appointed by the Italian government to investigate the vaccines which has now received over $50, 000 in funding to test all the vaccines and see if they are scams. And more, the Eugenicists are upset about WHERE the funding is coming from – top Italian medical science teams are funding Corvelva’s efforts, unlike what this Sott article implies in it’s headline and subsequently tries to state by claiming “scientists” are questioning the Italian government’s actions that the Italian government is off it’s rocker. That’s not what the headline should be. Here is what the headline should be:

FIVE NWO approved science scammers are protesting a vaccine safety investigation being conducted by Italy’s real top scientists who are rapidly and easily uncovering the truth about what the current childhood vaccines really are, and that they are not vaccines at all, they are something else entirely.

As it turns out, all it takes to find out what is really in the vaccines is to break rank, seize a sample of what is being injected into the children, put it in a real lab that is not compromised by kikes, and VOILA!!! suddenly it is known that the vaccines are not at all what they are claimed to be. You can’t do that in the United States. No parent is allowed to walk out the door with a shot that has not been injected into their kids, take it to a lab, and test it. This is NOT ALLOWED. WHY? Italy just got the answer.

The MSM is holding this topic by the gills at arm’s length like a diseased fish because of what Corvelva has found – that the vaccines really don’t have anything they are advertised for and are instead full on scams.

You can’t find a legitimate MSM report on this topic. Instead, the reports are all slander, calling Italians stupid, backwards, “conspiratorial”, against “established science” and anything else they can muster, and they HAVE TO because the vaccine eugenics programs are one of their greatest treasures, with carefully placed totally compromised despicable hateful and soulless people in all key positions to keep a lid on the scam and allow the destruction of our children proceed without a hitch.

Italy just blew the lid off the vaccine scam, and this one is not going away folks, Italy is NOT ZIMBABWE, they are clearly a first world country that can speak with authority. So the MSM is now trying to slander Italy because Italy uncovered one of kikedom’s NWO eugenics plots.

As if we did not all know the vaccines were wrecking our kids all along, – Gee, one in 35 kids now gets autism and “nobody can figure out why??” They know damn well at Newsweek, Sott and more. The entire shadow government KNOWS IT and now that Italy broke free of their grasp they are trying to bury it. Instead, they ought to just put a fork in it. THANKS ITALY for finally putting it in print from an official level. We knew it all along, but it is nice to get real confirmation from the top ranks of a first world government.”

Read Corvelva report:

Vaccinegate: Priorix Tetra analysis – 2nd step update

And now we know who is behind the vaccine agenda:

Coronavirus, QinetiQ, and the Rothschild Bombshell

Cold Case Reopened: Shows Virus Origins

Q is for the Queen’s Qinetiq

 

 

It Was An Overthrow By The Brits

It was an overthrow run by the Brits.

Please correct all those fake news channels calling it a “soft coup.” It was a hard coup.

It was a British attempt to overthrow the United States President.

It was conducted from the highest levels of the British inner Fleet Street cabal from the Queen, her Privy Council, the Pilgrims Society, and the media. This also includes: Alison Saunders’ conspiracy with Bruce and Nellie Ohr,  Arvinder Sambei with Robert Mueller, Robert Hannigan with John Brennan, Richard Dearlove, Mark Malloch-Brown, George Soros, Nick Clegg, Geoffrey Pattie.

Our AFI-AIM researchers are pulling out the TRUTH and the EVIDENCE daily from our research mines.

Call it what it is: ACT OF WAR

The British Monarch is enemy of the entire world. We must call for immediate action against the Queen and her co-conspirators for their crimes against humanity. All patriots around the world are called to action to free their nations and its citizens from the tyrannical rule of the British Empire. Historical facts don’t lie.

It Was An Overthrow By The Brits

.

Articles referenced in the audio are:

Wellcome and the Wee Little Death Box

.

Venetian Takeover of British Banking

.

July 29, 1909, 120 years ago, The Day Satan (disguised as a British White Supremacist) Took Charge Of The 20th Century

Hard proof that Britain is the source of modern weaponized intelligence and propaganda… to this day

COMMITTEE OF IMPERIAL DEFENCE [Subcomms MI5,MI6]. (Jul. 29, 1909). Committee Report that led to the founding of MI5 (Home Defence) and MI6 (Colonial Defence), HC Deb 29 July 1909 vol 8 cc1381-432. UK Parliament, Hansard.


https://www.fbcoverup.com/docs/library/1909-07-29-COMMITTEE-OF-IMPERIAL-DEFENCE-HC-Deb-29-July-1909-vol-8-cc1381-432-UK-Parliament-Hansard-Jul-29-1909.pdf

Committee of Imperial Defence. (Accessed Aug. 24, 2019). Committee Report to UK Parliament on Jul. 29, 1909 that led to the founding of MI5 (Home Defence) and MI6 (Colonial). Wikipedia.

https://www.fbcoverup.com/docs/library/2019-08-24-Committee-of-Imperial-Defence-Report-to-UK-Parliament-that-led-to-the-founding-of-MI5-Home-Defence-and-MI6-Colonial-Defence-Wikipedia-accessed-Aug-24-2019.pdf

Correspondent. (Jul. 23, 1909). EMPIRE PRESS UNION formed, published Sep. 07, 1909, Issue No. 14622, Dunedin, New Zealand via National Library of New Zealand, Ref. No. ODT19090907.2.6. Otago Daily Times.

https://www.fbcoverup.com/docs/library/1909-07-23-EMPIRE-PRESS-UNION-formed-published-Sep-07-1909-Issue-No-14622-Dunedin-New-Zealand-via-National-Library-of-New-Zealand-Ref-No-ODT19090907-2-6-Otago-Daily-Times-Jul-23-1909.pdf

Henry S. Wellcome. (Jun. 01, 1909 – ca. Jul. 1909). THE EVOLUTION OF JOURNALISM ETCETERA – International / Imperial Press Conference, 1909, Great Britain (incl. Lord Burnham, Sirs Edward and Harry Levy-Lawson). Burroughs Wellcome. FULLY INDEXED, BOOKMARKED, SEARCHABLE. 27.1 MB.

https://www.fbcoverup.com/docs/library/1909-06-01-THE-EVOLUTION-OF-JOURNALISM-ETCETERA-International-Press-Conf-1909-Pres-Lord-Burnham-Edward-Levy-Lawson-by-Henry-S-Wellcome-Burroughs-Wellcome-Jun-01-1909.pdf

The White Supremacists who ran cover for the establishment of MI5 and MI6 using the Imperial Press Conference, 1909 to recruit War Correspondents (Daily Telegraph, Daily Mail, Reuters, Financial Times, the Times, Manchester Guardian, Daily Express, BBC, New York Times, Chicago Tribune, Daily Mirror, Fleet Street, etc.) and (propaganda) writers from across the Commonwealth.

lawson wellcome.JPG

https://link.springer.com/chapter/10.1057/9780230508422_3

The Origins of British Counter-Espionage

boer war.jpg

p. 59 Fabian Ware, Editor, Morning Post

https://www.fbcoverup.com/docs/library/1909-06-01-THE-EVOLUTION-OF-JOURNALISM-ETCETERA-International-Press-Conf-1909-Pres-Lord-Burnham-Edward-Levy-Lawson-by-Henry-S-Wellcome-Burroughs-Wellcome-Jun-01-1909.pdf#page=59

p. 93 Lord Glenese, Sir Algernon Borthwick; Proprietor, Morning Post; President, Newspaper Press Fund

https://www.fbcoverup.com/docs/library/1909-06-01-THE-EVOLUTION-OF-JOURNALISM-ETCETERA-International-Press-Conf-1909-Pres-Lord-Burnham-Edward-Levy-Lawson-by-Henry-S-Wellcome-Burroughs-Wellcome-Jun-01-1909.pdf#page=93

https://galnet.fandom.com/wiki/Secret_Service_Bureau

UK Intelligence.png

https://api.parliament.uk/historic-hansard/commons/1909/apr/19/considered-in-committee

April 19, 1909

secret police 1.jpg

“We seem, since the inauguration of the Imperial Department of Criminal Intelligence, to be on the verge of constituting a Secret Police Force, and no innovation could be more dangerous and more liable to become a weapon of oppression with the material we are obliged to work through.”

Imperial Department of Criminal Intelligence

https://api.parliament.uk/historic-hansard/commons/1909/jul/29/committee-of-imperial-defence

COMMITTEE OF IMPERIAL DEFENCE

HC Deb 29 July 1909 vol 8 cc1381-4321381 (The Day the Empire Press Union was formed by delegates from the Imperial Conference just concluded)

Motion made, and Question proposed, “That a sum not exceeding £66,171 be granted to His Majesty to complete the sum necessary to defray the charge which will come in course of payment during the year ending on the 31st day of March, 1910, for the Salaries and Expenses in the Department of His Majesty’s Treasury and Subordinate Departments, including expenses in respect of advances under the Light Railways Act, 1896.”

The PRIME MINISTER (Herbert Asquith)

imperial conference 1.jpgimperial conference 2.jpgimperial conference 3.jpgimperial conference 4.jpg

.

british never left.jpg

RED ALERT Trump admin approves deadly food for Americans

Trump just signed an Executive Order giving the GMO industry full reign over seeds and crops with their frankenfood industry. We are livid. Who in the hell is advising him on GMOs, 5G, and social media technologies?

Let’s face it, President Trump may be a brilliant builder, billionaire, and deal-maker, but we have all seen what he eats – fast food and diet coke. Anyone knowledgeable about food, nutrition, and health would not be ingesting these poisons. Just coming after his approval of 5G, 6G, and higher, this executive order gives a green light for our food industry to become total poison.

We are huge supporters of POTUS just like many of our readers, but these decisions – from creating 5G killing fields to Monsanto killing fields, is not acceptable to us.

White House Issues Executive Order to Streamline Regulatory Review Process for Genetically Modified Farm Products

warning lightBecause we are leaving town, – we only have time for this quick blast to tell you RED ALERT RED ALERT. As AIM patriot AIM Patriot Denise writes us this morning:

I am writing because of the new executive order 13874 was signed by our President 6/11/2019 and I do not understand it. It seems that President Trump is saying it is alright to develop and send out to the world genetically engineered food but I could be misunderstanding.

You all are so smart that I was hoping you could take a look and let us know what you think.

I know you are busy so thank you so much in advance.

Denise, when we get back we will be writing an expose on why this is a horrible decision and why this executive order puts all Americans in jeopardy with even more health problems. Perhaps the president doesn’t understand what happens with GMOs.

Let’s use one simple example. McDonald’s doesn’t like how potatoes and apples brown when they are cut. Shortens the “shelf life”. The reason that fruits and vegetables brown is because the natural enzymes in the plant break down the pulp. Enzymes are extremely important in digestion and breaking down plant life. So the frankenfood industry creates a potato and apple that don’t brown. They genetically remove the plants’ enzymes. Now those potatoes and apples can last forever without turning brown.

Or take a look at the bag of veggies that you bought last month and are still in the bag…but haven’t browned a bit. Thanks to the frankenfood industry for removing the enzymes and irradiating the produce, the vegetables will now have long shelf lives.

The serious, life-threatening problem with this is that you eat these products and you cannot digest them. They have no enzymes so they cannot be properly eliminated from your body. The waste product sits in your gut and becomes toxic, creating all kinds of physical problems in your body.

We have written about this in one of our lessons from the ASCEND diet. Check it out: Clearing the Hara Chakra. You will also learn what happened in the Pottenger cat study when cats ate foods without enzymes over a few generations – they became sterile!

gut issues.JPG

Is that what President Trump and his administration are doing? Is he on a mission to keep Americans sick from frankenfoods up to a point that our young people will not reproduce? This coupled with his stand on 5G has us fuming.

Please start contacting the White House with your concern over this insanity. Contact White House.We must do a better job educating President Trump on this matter and we must demand a full retraction of this horrific executive order.

When we get back we will prepare a white paper and a few audios to help you educate and enlighten your circle of influence on how bad this will be for all Americans – living and future generations.

In the meantime, Vladimir Putin is protecting his citizenry from frankenfoods. Soon, all health-conscious Americans will be buying agricultural products from Russian organic farms. Vladimir Putin cares about the future health of his people. With the signing of this executive order and the continued promotion of 5G, it is clear that this administration is intent on sickening and killing us.

President Putin has his eyes set on shaking up worldwide organic food supplies with a new agricultural drive.

Let’s summarize.

deadly practices 2

.

Our babies are being harvested

Douglas Gabriel and Christopher Strunk – HARVESTED

For those of you that want to take this to the next level, read Strunk’s legal filings here:

CES Declaration in opposition to Fed MTD w EXHIBITS 51-88 filed 5-28-19

CES MOL in response to FED MTD NDNY 19-cv-202

Here are two other relevant audios that Chris did earlier on teh subject of human harvesting.

Baby Harvesting must be stopped

Nazi Human Medical Experiments in America

The Truth About Endocannabinoids

The American Intelligence Media community is interested in finding truth wherever it may be – from politics and culture to health and finance. Lately, Douglas Gabriel has been researching the properties of cannabinoids. In this summation of several articles that Douglas reviewed, he offers this white paper to help our truth community get up-to-speed on the endocannabinoid system.

To get started, this video below provides a general overview on the endocannabinoid systems.

Cannabis and the endocannabinoid system

 

The Wonders of CBDs

Cannabinoids are the chemical compounds made by the cannabis plant that unlock its many healing secrets. There are over 100 known cannabinoids and these chemicals imitate the endocannabinoids naturally produced in the human body. The shiny little crystals you see on cannabis buds are called trichomes where cannabinoids are stored. Human bodies (and many animals) have endocannabinoid systems (ECS), meaning that cannabinoids are naturally made so they can bind to endocannabinoid receptors creating changes in our physiology.

cannabis bud.jpg
The shiny little crystals you see on cannabis buds are called trichomes.

To understand the master gland and immune system of the human body it is crucial to have a basic understanding of the endogenous cannabinoid system, otherwise known as the endocannabinoid system (ECS). The endocannabinoid system is essential to human health because it maintains homeostasis in the body. Research into the endocannabinoid system has increased in recent years as scientists begin to reveal how complex and important this system is to our bodies.

The legal cannabis movement started in San Francisco in the early 1990’s when it was discovered that cannabis treated many symptoms that AIDS patients suffered from, including pain. It was medical marijuana laws that changed the legal status of cannabis nationwide, opening the doors for research and an adult-use market and creating a path towards full legalization. Cannabis patients across the country have used the plant to treat a growing number of medical conditions. In Colorado alone, there are nine different qualifying conditions for a medical card: cancer, glaucoma, HIV or AIDS, cachexia (wasting syndrome), persistent muscle spasms, seizures, severe nausea, severe pain, and Post Traumatic Stress Disorder (PTSD).

What Do CBD’s Do?

The endocannabinoid system (ECS) is responsible for maintaining homeostasis in the body. Homeostasis is defined as: “any self-regulating process by which biological systems tend to maintain stability while adjusting to conditions that are optimal for survival.” If homeostasis is successful, life continues; if unsuccessful, disaster and ill health ensues.

The endocannabinoid system is made up of three parts: cannabinoid receptors, endocannabinoids, and metabolic enzymes.

  • Endocannabinoid receptors are found throughout the body on the surface of cells in the brain, organs, tissues, and glands. These receptors are embedded in cell membranes and produce varying reactions when stimulated by cannabinoids.
  • Cannabinoids come from two distinct places — the body, which produces naturally occurring endocannabinoids, and foods like the cannabis plant, which produces phytocannabinoids.
  • Metabolic enzymes act like a natural referee in that they destroy endocannabinoids once they are used up by the body. The two main metabolic enzymes are fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).

This self-regulating system ensures the interaction of CBDs with the ECS only happens when needed and therefore keeps the workings of the endocannabinoid system relatively quiet to the conscious brain. Because homeostasis is so important to health, all vertebrates and invertebrates are known to have an endocannabinoid system.

Cannabinoids can also be produced synthetically. Marinol (dronabinol) and Cesamet (nabilone) are synthetic versions of THC that have FDA approval to be marketed and sold as a prescription drug. Synthetic cannabinoids do unlock the endocannabinoid system to produce effects, but they often fail to incorporate the entourage effect which states that the sum of the different cannabinoids works better as a whole unit than any cannabinoid individually. With an understanding of the endocannabinoid system and its role in ensuring homeostasis in the body, it may be easier to see how this could be true.

The Endocannabinoid System

Despite its critical importance, the endocannabinoid system (ECS) was only discovered in the early 1990s when Lisa Matsuda, a researcher at the National Institute of Mental Health, and her colleagues discovered a DNA sequence that defines a THC-sensitive receptor in a rat’s brain. This discovery was quickly followed up with further evidence by Dr. Raphael Mechoulam, the famous chemist who discovered THC. With less than 30 years of research, the endocannabinoid system is one of the least studied systems in the body. Currently, restrictions on cannabis research limit what scientists can examine in terms of furthering the understanding of how cannabis and hemp interact with the endocannabinoid system.

Two cannabinoid receptors have been discovered by researchers: CB1 and CB2. CB1 is found in the central and peripheral nervous system. It’s also found in the brain and is the receptor that THC interacts with, giving the user a “high.” CB2 receptors are predominantly found in the immune system and the gastrointestinal system where they regulate inflammatory responses in the bowels. CB2 receptors are also found in the brain, although not as densely as CB1 receptors. These receptors, a large part of the endocannabinoid system, play roles in regulating cardiovascular activity, appetite, mood, memory, and pain in the body.

CBD does not fit exactly into either CB1 or CB2 receptors. CBD stimulates both receptors and causes a reaction without binding directly, creating changes in cells that contain them. CBD also binds to a protein-receptor couple, TRPV-1, responsible for regulating body temperature, pain, and inflammation. CBD is also known for counteracting the effects of THC, activating serotonin receptors, and inhibiting a gene attributed to several cancers. CBD has grown in popularity recently as research and anecdotal evidence increasingly demonstrates the impact it can have on the body.

The body’s endocannabinoid system reacts to CB1 and CB2 based upon the organ or bodily system that is sensitive to one or both. The brain is especially sensitive to CB1, the lungs to CB1, the spleen to CB2, the vascular system CB1, the pancreas to CB1 & CB2, the liver to CB1 & CB2, reproductive organs to CB1, the colon to CB2, the muscles to CB1, the immune system to CB2, and the bones to CB2.

The endocannabinoid system (ECS) is also involved in regulating a variety of physiological and cognitive processes including fertility, pregnancy (during pre- and postnatal development) appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of cannabis. The ECS is also involved in mediating some of the physiological and cognitive effects of voluntary physical exercise in humans and other animals, such as contributing to exercise-induced euphoria as well as modulating locomotor activity and motivational salience for rewards.

In humans, the plasma concentration of certain endocannabinoids (i.e., anandamide) have been found to rise during physical activity; since endocannabinoids can effectively penetrate the blood–brain barrier, it has been suggested that anandamide, along with other euphoriant neurochemicals, contributes to the development of exercise-induced euphoria in humans, a state colloquially referred to as a runner’s high.

Cannabinoids

Cannabinoids are broadly known for their anti-seizure, anti-inflammatory, anti-nausea, anti-fungal, and anti-cancer effects — and science has just scratched the surface. How much these effects are expressed is a result of the entourage effect is not fully known. The entourage effect states that the cannabinoids work better in tandem than they do alone. THC and CBD produce stronger healing properties together that are shown differently based on their concentrations and the presence of other cannabinoids. In addition, terpenes, the oils that give cannabis its fragrance, contribute to the therapeutic effects of the plant on the body when paired with cannabinoids. The powerful combination of these naturally occurring chemicals produces the medical effects that have given cannabis its reputation as a wondrous medical agent.

In California, there are twelve qualifying conditions for a medical cannabis card, including one described as, “any other chronic or persistent medical symptom that substantially limits the ability of the person to conduct one or more major life activities (as defined by the Americans with Disabilities Act of 1990) or, if not alleviated, may cause serious harm to the patient’s safety or physical or mental health.”

There are over 100 known cannabinoids and we’ve only briefly described a few. There is a lot more research to be done to understand the intricacies of each cannabinoid and how they interact with each other.

Cannabinoids can bind to receptor sites in either the brain (CB-1) or the body (CB-2). Cannabinoids will produce different effects on the body depending on which type of receptor site they bind to. Cannabis strains are filled with multiple cannabinoids that when consumed, bind to these sites, creating a symphony of effects on the body and thus corresponding to the wide variety of healing properties. This is why one plant can treat many different conditions.

Cannabinoids begin as cannabinoid acids that are activated when heated. This heat-based activation, also known as decarboxylation, removes the acid from the molecule, turning it into a bioavailable compound that the body can register. The decarboxylated molecule is often more powerful and produces a different effect on the body than the acidic version. This is why you see both “THCA” and “THC” when looking at the contents of a cannabis strain.

Here is a list of a few of the well-known types of cannabinoids and their effects: 

THCA

Delta 9 THC is arguably the most widely known cannabinoid. When people refer to “getting high” they are referring to the experience of the psychoactive effects of THC. THC begins as THCA, tetrahydrocannabinolic acid, which is one of the most abundant cannabinoids found in cannabis. When THCA is heated and turned into THC, it binds to CB1 receptors in the brain producing psychoactive effects. THC is the only known cannabinoid to produce a psychoactive response, a high, and strong therapeutic benefits. 

CBDA
Cannabidolic acid is very abundant in the cannabis plant and turns into CBD when heated. Preclinical studies demonstrate that CBDA is a strong antiemetic used to treat vomiting and nausea and is often given to mitigate the side effects of opioid use or chemotherapy. 

CBD
Cannabidiol has exploded in popularity in recent years. CBD has been the subject of much scientific interest after it hit the mainstream in 2014, following a CNN documentary in which a non-psychoactive, CBD rich cannabis strain, helped a five-year-old girl with severe epilepsy drastically reduce her daily seizure count. The FDA has approved the first ever CBD-based drug for seizures. CBD is making waves in its ability to treat pain, nausea, anxiety, sleep disorders, and more. 

CBGA
Cannabigerolic acid is a precursor to one of the three main cannabinoid lines: THCA, CBDA, and CBCA. CBGA is the chemical parent to THC and CBD. Enzymes direct it down one of these lines before heat can change it into different forms. CBGA can help reduce inflammation and relieves pain. 

CBG
Cannabigerolic is considered a minor cannabinoid because it is present in very low levels. It’s also powerful in treating glaucoma because it is a strong vasodilator meaning that it widens blood vessels. This helps increase blood flow and provide oxygen to the tissues that need it. CBG is showing promise as an effective antibacterial, anticancer, and neuroprotectant. 

CBCA
Cannabichromenic acid is one of the three main cannabinoid lines. It is used to treat fungal infections like athlete’s foot and ringworm. 

CBC
Cannabichromenic, binds poorly to CB1 receptors in the brain, but it binds well with other pain-related receptors, helping to increase the body’s levels of natural endocannabinoids. CBC may be impactful against cancer because of this. CBC has also been shown to be an inhibitor of acne. In conjunction with the THC and CBD, CBD also appears to have antidepressant effects. 

CBN
Cannabinol is the result of THCA over time breaking down and turning into CBN. CBN has been shown to delay symptom onset of Lou Gehrig’s disease in mice indicating that it may help with motor neural diseases. CBN is also known for its anti-asthmatic, anti-inflammatory, and sedative properties. 

THCV
Tetrahydrocannabivarin is similar to THC, but with a few less carbon atoms. THCV has been shown to be an anticonvulsant, has neuroprotective properties and may be an appetite suppressant. 

CBDV
Cannabidivarin is a less potent version of CBD. The CBDV molecule is similar to CBD but has been changed in some ways. CBDV is an anti-nausea and anti-epileptic. CBDV is a powerful anticonvulsant. A 2012 study shows that CBDV stopped seizures in mice and rats. 

In general, CBDs, cannabidiols, can be taken into the body in different ways – from smoking cannabis to eating CBD-rich food substances, as a drink, as an aerosol spray into the cheek, or transdermally. CBD oil, containing only CBD derived from hemp as the active ingredient, is legal in all 50 States and has no tetrahydrocannabinol (THC) in the oil. Some types of CBD oil may contain THC or one of many other CBD-like compounds that can be refined into a distillate and then made into oils, pills, foods, candies, drinks, many forms of hash, salves, creams, and many other substances used as medicine.

Other Foods that Contain CBDs

You may be surprised to know that cannabinoids aren’t limited to their presence within cannabis and hemp plants and feature in many household foodstuffs that you probably already have in your kitchen. The cannabinoids that are produced in plants are called phytocannabinoids. So, if you want to enhance your body’s own endocannabinoid system, look at the following list of foods and consider adding them to your diet.

Black Pepper contains the terpene beta-caryophyllene (BCP) that will bind to the same cannabinoid receptors that THC does and produces a calming, relaxing effect and is also known for its anti-inflammatory action. Current research is going on into BCP’s effects within cancer treatment and for conditions such as arthritis and osteoporosis. To achieve instant and natural calming effects, it is recommended to eat 3 or 4 cloves (high in BCPs) or use them in cooking or teas.

Dark Chocolate that contains cacao as its main ingredient is high in anandamide. Cacao or its full name Theobroma Cacao (translates as “food of the gods”) has been known to be a superfood for millennia. It contains a high concentration of a cannabinoid called anandamide, which is also naturally produced in the body. Anandamide is known as the body’s own natural antidepressant and is often referred to as the human body’s natural version of THC.

Rosemary, Cloves, Basil, Oregano, Lavender & Cinnamon all contain cannabinoids, most commonly beta-caryophyllene (BCP). The terpene’s present in these herbs help contribute to the specific aroma that each one has. These terpenes are also present in marijuana plants and contribute to their aromas.

Hops – humulus lupulus – share a common ancestor with the cannabis family of plants if you follow the history back to the Order Urticales and the Family Cannabinaceae — they share similar properties genetically.

Flax Seed has many compounds within it that are very similar to the cannabinoid cannabidiol (CBD) as well as containing CBD itself. The CBD within flax has anti-inflammatory properties and develops autoimmune response.

CBD Legal Status

In the United States, CBD’s legal status depends on the source from which it is derived. When derived from marijuana it is a Schedule I controlled substance under the federal Controlled Substances Act (CSA). When CBD is derived from hemp or some other lawful source it is not a controlled substance. Hemp is excluded from the definition of marijuana under the Controlled Substances Act (CSA). CBD is not specifically scheduled in the CSA and is therefore lawful when derived from hemp, which is not a controlled substance and the definition of which includes cannabinoids.

In 2013, a CNN program brought increased attention to the use of CBDs in the treatment of seizure disorders. Since then, 16 states have passed laws to allow the use of CBD products with a doctor’s recommendation (instead of a prescription) for treatment of certain medical conditions. This is in addition to the 30 states that have passed comprehensive medical cannabis laws, which allow for the use of cannabis products with no restrictions on THC content. Of these 30 states, eight have legalized the use and sale of cannabis products without requirement of a doctor’s recommendation.

The 2014 Farm Bill legalized the sale of “non-viable hemp material” grown within states participating in the Hemp Pilot Program. This legislation defined hemp as cannabis containing less than 0.3% of THC delta-9, grown within the regulatory framework of the Hemp Pilot Program. The 2018 Farm Bill allowed for interstate commerce of hemp derived products (CBD oil), though these products still fall under the purview of the FDA.

Legal CBD Oil and Your Health

The body’s endocannabinoid system is vital for the overall balance of the immune system, sleep, the digestive tract, cognitive functioning, and the health of the nervous system. Hemp extract, which is legal in all 50 States (CBD oil) has been shown to provide incredible support to the human endocannabinoid system. Numerous studies have proven CBD oil to relieve chronic pain, reduce anxiety and depression, as well as benefit heart health and many other ailments. Also, hemp extracted CBD oil has been used to treat patients diagnosed with Parkinson’s, Alzheimer’s, diabetes, and even cancer with positive effects.

cbd oilAccording to an article published in Forbes in 2018, the CBD market is looking to grow 700% by the year 2020 because of positive health benefits experienced by a growing number of individuals. According to a new estimate from cannabis industry analysts The Brightfield Group, the hemp CBD market alone could hit $22 billion by 2022.

Skeptics who assume CBD is just 21st-century snake oil, may be surprised to learn that the substance is being studied as a potential treatment for maladies as diverse as schizophrenia, insomnia and cancer.

“CBD is the most promising drug that has come out for neuropsychiatric diseases in the last 50 years,” said Dr. Esther Blessing, an assistant professor at New York University School of Medicine, who is coordinating a study of CBD as a treatment for post-traumatic stress disorder and alcohol use disorder. “The reason it is so promising is that it has a unique combination of safety and effectiveness across of very broad range of conditions.”

The National Institutes of Health database lists about 150 studies involving CBD as a treatment for conditions as varied as infantile spasms and Parkinson’s disease. And the research has led to medical treatments. The Food and Drug Administration approved a cannabidiol-based drug called Epidiolex as a treatment for severe forms of epilepsy, representing the first government-sanctioned medical use for CBD. Preliminary research also indicates that CBD may be effective as an antipsychotic in reducing the symptoms of schizophrenia, with fewer side effects compared with current antipsychotic drugs.

CBD has also shown promise to reduce cravings among people addicted to opioids, according to a study published in Neurotherapeutics in 2015. It may fight cancer, too. The authors of a review published in the British Journal of Clinical Pharmacology in 2012 wrote: “evidence is emerging to suggest that CBD is a potent inhibitor of both cancer growth and spread.”

CBDs and Evolution

What is the evolutionary impetus for the creation of cannabinoids? Even single-cellular organisms like cyanobacteria – the descendant of the original photosynthetic bacteria – produce chemicals that act on cannabinoid receptors. But the cannabinoid receptors evolved much later, first appearing in the ancient Hydra (not the god) around 500 million years ago.

It is still unclear why plants produce cannabinoids without corresponding receptors to bind with. Some insects do the same. There may be an undiscovered mechanism by which plants regulate themselves with phytocannabinoids that has yet to be found – like so many other aspects of the ECS. In humans, the ECS has developed into a homeostatic system – a fundamental adaptive mechanism that enables our bodies to maintain health through the stresses of life.

CBDs are all the rage these days and has become a wellness craze. Unfortunately, it is fashionable to fixate on a single cannabis component. But we should not lose sight of the fact that well-known herbal medicine provides countless remedies relevant to modern disease. Ultimately, purified pharmaceuticals are not inherently superior to multicomponent, whole plant formulations. These whole plant remedies have been used for millennia and we would be well-advised to not forget the wisdom of the ancients.

At this point in time, single-molecule CBD and single-molecule THC are both FDA-approved medications. The medical development of cannabinoids should build upon traditional knowledge and herbal folk-wisdom, which often involved a mixture of various CBD herbs and foods, including CBD-rich cannabis, which has been part of the human pharmacopeia for thousands of years. At least with herbs we have a long, successful history, while novel pharmaceutical development is experimental without many longitudinal studies.

History, on the other hand, has proven that hemp and other CBD rich foods, herbs, drinks and spices have been at the heart of the human diet since our first ancestors discovered CBD-rich nourishment which is crucial for human health. As we welcome hemp and cannabis back into the pantheon of medicinal herbs, let’s honor the “crude” plants that have sustained humankind since time immemorial.